Fusion Protein for Tumor-Specific Prodrug Activation
Author Information
Author(s): K. Bosslet, J. Czech, P. Lorenz, H.H. Sedlacek, M. Schuermann, G. Seemann
Primary Institution: Research Laboratories of Behringwerke AG; Institute for Molecular Biology and Tumor Research
Hypothesis
The fusion protein consisting of a humanized antibody and human β-glucuronidase can effectively activate prodrugs specifically at tumor sites.
Conclusion
The study demonstrates that the fusion protein can bind to tumor cells and activate a prodrug, showing potential for targeted cancer therapy.
Supporting Evidence
- The fusion protein showed similar binding characteristics to the original murine antibody.
- Two molecular forms of the fusion protein were identified with distinct molecular weights.
- The fusion protein was enzymatically active and demonstrated stability at different pH levels.
- Histochemical evaluations confirmed the specificity of the fusion protein for tumor tissues.
Takeaway
Scientists created a special protein that can help turn a harmless medicine into a strong cancer-fighting drug right where the tumor is.
Methodology
The fusion protein was expressed in BHK cells and its activity was tested using various assays, including avidity determination and histochemical evaluations.
Limitations
The treatment became inefficient due to the fast activation of a neutralizing immune response against the enzyme.
Participant Demographics
Five patients with advanced colorectal carcinomas were treated.
Want to read the original?
Access the complete publication on the publisher's website